Topical Timolol for the Treatment of Benign Vascular Periocular Lesions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01250457 |
Recruitment Status :
Withdrawn
(Unknown, PI has left the institution. There was no enrollment.)
First Posted : November 30, 2010
Last Update Posted : October 30, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Benign Vascular Periocular Lesions | Drug: topical Timolol | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Topical Timolol for the Treatment of Benign Vascular Periocular Lesions |
Study Start Date : | June 2010 |
Actual Primary Completion Date : | July 2012 |
Actual Study Completion Date : | July 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Topical timolol
topical Timolol 0.5% solution applied twice daily
|
Drug: topical Timolol
topical Timolol 0.5% solution applied twice daily
Other Name: Timoptic |
- lesion resolution [ Time Frame: 1 year ]Pre-treatment and post-treatment lesion size will then be compared to determine whether twice-daily topical application of timolol 0.5% solution alters the morphometry of benign vascular periocular lesions.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Presence of a benign vascular periocular lesion
Exclusion Criteria:
- Allergy to timolol or beta-blocker class of drugs
- Lesion characteristics concerning for atypia or malignancy including madarosis, ulceration, and recurrence after previous surgery.
- Intraocular Pressure less than 10 mm Hg

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01250457
United States, Illinois | |
Loyola University Medical Center | |
Maywood, Illinois, United States, 60153 |
Principal Investigator: | David Yoo, MD | Loyola University |
Responsible Party: | Loyola University |
ClinicalTrials.gov Identifier: | NCT01250457 History of Changes |
Other Study ID Numbers: |
202688 |
First Posted: | November 30, 2010 Key Record Dates |
Last Update Posted: | October 30, 2012 |
Last Verified: | October 2012 |
Timolol Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents |